IRIS PubliCatt

Andreotti, Felicita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.842
EU - Europa 2.332
AS - Asia 805
AF - Africa 16
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 8
Totale 6.025
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.826
SE - Svezia 656
CN - Cina 523
DE - Germania 504
IT - Italia 310
IE - Irlanda 210
UA - Ucraina 209
SG - Singapore 148
FR - Francia 112
GB - Regno Unito 102
RU - Federazione Russa 88
FI - Finlandia 51
TR - Turchia 35
IN - India 33
BE - Belgio 18
NL - Olanda 14
KR - Corea 12
IR - Iran 11
BR - Brasile 9
CZ - Repubblica Ceca 9
ET - Etiopia 9
HK - Hong Kong 9
AU - Australia 8
CH - Svizzera 8
EU - Europa 8
JP - Giappone 8
MX - Messico 7
PL - Polonia 6
VN - Vietnam 6
AT - Austria 5
RO - Romania 5
BG - Bulgaria 4
CA - Canada 4
DO - Repubblica Dominicana 4
ES - Italia 4
TW - Taiwan 4
CI - Costa d'Avorio 3
KW - Kuwait 3
QA - Qatar 3
ZA - Sudafrica 3
BT - Bhutan 2
CL - Cile 2
HU - Ungheria 2
IL - Israele 2
LU - Lussemburgo 2
PT - Portogallo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BZ - Belize 1
CO - Colombia 1
DK - Danimarca 1
GR - Grecia 1
ID - Indonesia 1
IQ - Iraq 1
LI - Liechtenstein 1
LT - Lituania 1
LV - Lettonia 1
MC - Monaco 1
ME - Montenegro 1
MK - Macedonia 1
MU - Mauritius 1
NO - Norvegia 1
OM - Oman 1
PK - Pakistan 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 6.025
Salva come PNG Salva come JPEG
Città #
Chandler 593
Ashburn 337
Dublin 203
San Mateo 159
Hangzhou 115
Wilmington 112
Jacksonville 105
Beijing 98
Nanjing 98
Cattolica 93
Singapore 93
New York 91
Boston 85
Princeton 82
Moscow 68
Milan 66
Ann Arbor 54
Menlo Park 52
Lancaster 50
Bremen 49
Redwood City 37
Dearborn 35
Fairfield 34
Nanchang 34
Rome 34
Woodbridge 34
Marseille 33
Lawrence 29
Los Angeles 29
Seattle 28
Izmir 27
Munich 27
Houston 26
Chicago 24
Boardman 21
Mountain View 18
Nürnberg 18
Redmond 17
Brussels 16
Norwalk 16
Shenyang 15
Pune 14
Hebei 12
Kunming 12
Zhengzhou 12
Padova 11
Washington 11
Augusta 10
Jiaxing 10
Leawood 10
Shanghai 10
Tianjin 10
Busto Arsizio 9
Changsha 9
Detroit 8
Groningen 8
University Park 8
Andover 7
Florence 7
Guangzhou 7
Zhongxin 7
Cambridge 6
Gunzenhausen 6
Hanoi 6
Hong Kong 6
Cuautitlán Izcalli 5
London 5
Vienna 5
Dallas 4
Hefei 4
Istanbul 4
Kish 4
Lappeenranta 4
San Diego 4
Santa Maria 4
Santo Domingo 4
Seoul 4
Sofia 4
Suwon 4
Zurich 4
Abakan 3
Abidjan 3
Arezzo 3
Atlanta 3
Brno 3
Doha 3
Edinburgh 3
Frankfurt am Main 3
Fremont 3
Helsinki 3
Hyderabad 3
Kuwait City 3
Maastricht 3
Madrid 3
Ningbo 3
Perth 3
Southend 3
Taizhou 3
Toronto 3
Wuhan 3
Totale 3.494
Salva come PNG Salva come JPEG
Nome #
Antiplatelet agents for the treatment and prevention of atherothrombosis 161
Effect of pravastatin on endothelial function and endothelial progenitor cells in healthy postmenopausal women 148
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 142
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function 114
Ximelagatran/melagatran against conventional anticoagulation: A meta-analysis based on 22,639 patients 113
Intraventricular conduction abnormalities in young patients with type 1 diabetes mellitus 111
Impact of coronary stenting on top of medical therapy and of inclusion of periprocedural infarctions on hard composite endpoints in patients with chronic coronary syndromes: a meta-analysis of randomized controlled trials 103
IGF-1 and microvascular complications of diabetes: alternative interpretation of recently published data 89
Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction 89
Body fat and cardiovascular risk: understanding the obesity paradox 86
Bedside monitoring of antiplatelet therapy for coronary stenting 83
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials 80
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 80
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 78
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology 77
Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome 77
Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS) 76
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 76
A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age. 75
Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 75
Testosterone, tissue factor inhibition and vascular aging 73
Sex differences in mechanisms, presentation and management of ischaemic heart disease 69
Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology 68
Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies 68
Anemia contributes to cardiovascular disease through reductions in nitric oxide 68
Mechanisms, pathophysiology, and management of obesity 68
Hemoglobin levels, nitric oxide bioavailability and cardiovascular outcomes 64
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 64
Last word on viewpoint: Anemia contributes to cardiovascular disease through reductions in nitric oxide 63
EuroThrombosis: annual meeting of the European Society of Cardiology Working Group on Thrombosis 61
Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor 61
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis 60
Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials 58
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis 58
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 58
Intracoronary bolus of glycoprotein IIb/IIIa inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of STEMI 58
Polycythemia, vascular function, and hemoglobin-nitric oxide reactions 57
Bedside monitoring of antiplatelet therapy for coronary stenting 57
Mechanisms, Pathophysiology, and Management of Obesity 57
The unstable plaque: a broken balance 56
Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials 56
Leading avoidable cause of premature deaths worldwide: case for obesity 55
[Inflammatory and fibrinolytic activation after coronary artery bypass with extracorporeal circulation] 54
Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: A jump with a weak parachute? 53
Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization 53
The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? 53
Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation 53
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety 52
Women and coronary disease 52
Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients 52
Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes 52
Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism 51
Doppler Ultrasound Monitoring of Echogenicity in Asymptomatic Subcritical Carotid Stenosis and Assessment of Response to Oral Supplementation of Vitamin K2 (PLAK2 Randomized Controlled Trial) 51
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper 50
Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: A systematic review and meta-analysis 50
Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives 49
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 49
Role of PAPP-A in atherothrombosis: messages to take home 48
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis 48
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 48
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management 47
Normothermia does not improve postoperative hemostasis nor does it reduce inflammatory activation in patients undergoing primary isolated coronary artery bypass 46
Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery 46
Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: A review 46
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS 46
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis 46
Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis 45
Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: Not a matter of faith 44
The G20210A prothrombin mutation and the Physicians' Health Study 43
G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 43
Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials 43
Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention? 43
4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: A prospective study 42
The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population 42
Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromes 42
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 41
G20210A prothrombin gene polymorphism and extent of coronary disease 41
Family history in first degree relatives of patients with premature cardiovascular disease 41
Sex- and gender‑specific precision medicine for chronic coronary syndromes: challenges and opportunities 41
Stakeholders in NOACs prescription: Authors' reply 40
Reversible left anterior descending artery spasm, prolonged cardiac arrest and left main thrombosis during a PTCA attempt of the circumflex artery 40
Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions 40
Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy: A systematic review and meta-analysis 39
Prolonged endogenous fibrinolysis predicts reduced survival after acute coronary syndromes 39
Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry 39
Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure 39
Defining the role of left atrial appendage closure in atrial fibrillation 38
Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine 38
Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation 35
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: The 'OPTIMIZE-IT' pilot randomized study 35
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial 35
Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease 32
Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering a systematic review and meta-analysis 32
Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel 31
Methodological education in response to the quality of COVID-19 publications 31
Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis 30
Fibrinogen as a marker of inflammation: a clinical view 29
Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-A systematic review and network meta-Analysis 29
Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal 28
Glycoprotein la C807T qene polymorphism and increased risk of recurrent acute coronary syndromes: A five year follow up 27
Totale 5.762
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.899
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.899
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020397 0 11 16 20 28 35 35 18 49 26 77 82
2020/2021520 63 52 7 42 60 32 58 8 64 18 110 6
2021/2022912 73 62 8 65 50 23 20 162 39 50 192 168
2022/20231.918 305 251 143 247 138 226 77 149 243 41 66 32
2023/20241.150 44 286 21 152 29 137 59 105 25 41 133 118
2024/202571 44 27 0 0 0 0 0 0 0 0 0 0
Totale 6.164